Aberdeen Group plc Increases Position in Pfizer Inc. $PFE

Key Points

• Aberdeen Group plc increased its stake in Pfizer Inc. by 6.9%, owning over 5.27 million shares valued at approximately $128 million as of the end of the second quarter.
• Multiple institutional investors have also increased their holdings in Pfizer, with Vanguard Group and Amundi reporting increases of 0.9% and 43.4%, respectively, in the first quarter.
• Pfizer recently announced a quarterly dividend of $0.43, which represents an annualized dividend yield of 6.9% and will be paid on December 1st to stockholders of record.

Aberdeen Group plc grew its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 6.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,272,611 shares of the biopharmaceutical company's stock after acquiring an additional 338,461 shares during the quarter. Aberdeen Group plc owned about 0.09% of Pfizer worth $128,098,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in shares of Pfizer by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company's stock valued at $13,257,004,000 after acquiring an additional 4,629,976 shares during the period. Northern Trust Corp increased its holdings in shares of Pfizer by 6.8% in the 1st quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company's stock valued at $1,579,340,000 after acquiring an additional 3,943,397 shares during the period. Amundi increased its holdings in shares of Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock valued at $1,265,277,000 after acquiring an additional 15,758,846 shares during the period. Invesco Ltd. boosted its position in shares of Pfizer by 2.8% in the 1st quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company's stock worth $767,709,000 after purchasing an additional 838,198 shares in the last quarter. Finally, Deutsche Bank AG boosted its position in shares of Pfizer by 7.0% in the 1st quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company's stock worth $715,581,000 after purchasing an additional 1,846,436 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on PFE. UBS Group reissued a "neutral" rating and issued a $28.00 price objective on shares of Pfizer in a research report on Wednesday, October 1st. Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Weiss Ratings reissued a "hold (c-)" rating on shares of Pfizer in a research report on Wednesday. Morgan Stanley lowered their price objective on Pfizer from $33.00 to $32.00 and set an "equal weight" rating for the company in a research report on Friday. Finally, Wall Street Zen cut Pfizer from a "buy" rating to a "hold" rating in a research report on Sunday, September 28th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $28.35.

Pfizer Stock Performance

Shares of PFE opened at $24.81 on Friday. The stock has a 50-day moving average of $24.86 and a two-hundred day moving average of $24.14. Pfizer Inc. has a one year low of $20.92 and a one year high of $29.82. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The stock has a market cap of $141.03 billion, a P/E ratio of 13.19, a P/E/G ratio of 0.83 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter in the previous year, the firm posted $0.60 EPS. The firm's revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer's payout ratio is 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.